THE BLOOD PLASMA LEVEL OF HIGH SENSITIVITY C-REACTIVE PROTEIN AND MARKERS OF CHRONIC INFLAMMATION IN PATIENTS WITH ATRIAL FIBRILLATION, ARTERIAL HYPERTENSION, CORONARY ARTERY DISEASE AND HEART FAILURE

Yalovenko M. I.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The object of study was to evaluate the manifestation of chronic inflammation in patients with atrial fibrillation, arterial hypertension, coronary artery disease and heart failure. Material and methods. 78 patients were examined; average age was 66,3 ± 1,0. The 1 group included 42 patients with permanent form of atrial fibrillation (AF), arterial hypertension (AH), coronary artery disease (CAD) and heart failure (HF). The 2 group consisted of 36 patients with AH, CAD, HF without heart rhythm disturbances. 15 practically healthy persons were included in control group. In all groups patients were comparative by age, sex and clinical manifestation. Blood plasma levels of high sensitivity C-reactive protein (hs-CRP), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10) were measured in the patients of the 1 and 2 groups as well as control group. 12-lead electrocardiography (ECG), 24-hour monitoring of electrocardiogram and blood pressure, transthoracic echocardiography (TTE) were performed for all patients. Results. In the patients of 1 group the significant increase of blood plasma levels of hs-CRP (5,04 ± 0,31 mg/L vs 2,98 ± 0,09 mg/L, р = 0,001), ІL-1 (12,34 ± 1,35 pg/mL vs 3,48 ± 0,46 pg/mL, р = 0,001), ІL-6 (10,27 ± 0,93 pg/ mL vs 5,04 ± 0,36 pg/mL, р = 0,002) were revealed in comparison with control group. In the patients of 2 group the significant increase of blood plasma levels of hs-CRP (4,11 ± 0,35 mg/L vs 2,98 ± 0,09 mg/L, р = 0,05), IL-1 (8,77 ± 1,44 pg/mL vs 3,48 ± 0,46 pg/mL, р = 0,02), ІL-6 (8,18 ± 0,77 pg/mL vs 5,04 ± 0,36 pg/mL, р = 0,01) were revealed in comparison with control group. In the patients of 1 group the tendency to increase of blood plasma levels of hs-CRP (5,04 ± 0,31 mg/L vs 4,11 ± 0,35 mg/L, р = 0,09), ІL-1 (12,34 ± 1,35 pg/mL vs 8,77 ± 1,44 pg/mL, р = 0,07), ІL-6 (10,27 ± 0,93 pg/mL vs 8,18 ± 0,77 pg/mL, р = 0,09) were revealed in comparison with 2 group. In the patients of 1 group the significant increase of blood plasma level of IL-10 (29,01 ± 2,59 pg/mL vs 15,43 ± 1,80 pg/mL, р = 0,001) was revealed in comparison with 2 group as well as between 1 group and control group (29,01 ± 2,59 pg/mL vs 11,14 ± 1,58 pg/mL, p = 0,001). In the patients of 2 group the tendency to increase level of IL-10 (15,43 ± 1,80 pg/mL vs 11,14 ± 1,58 pg/mL, р = 0,13) was revealed in comparison with control group. Conclusion. In patients with permanent form of AF, AH, CAD and HF the significant increase of blood plasma levels of hs-CRP, IL-1, IL-6 and IL-10 were revealed; that indicates the presence of chronic inflammation. Consequently, the main strategy of treatment of patients with a permanent form of AF, AH, CAD and HF is to suppress the activity of chronic inflammation, as one of the leading pathogenetic mechanisms of progression of the atherosclerotic process and heart rhythm disturbances, with obligatory using of the inhibitors of the renin-angiotensin-aldosterone system and statins.

permanent atrial fibrillation, arterial hypertension, coronary artery disease, heart failure, cytokines

1. Mensah GA. An overview of cardiovascular disease burden in the United States. Health Affairs. 2007;26(1):38-48. Available from: https:// www.healthaffairs.org/doi/pdf/10.1377/hlthaff.26.1.38
2. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. Drug Des Devel Ther. 2010;4:383-413. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21267417
3. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;12. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24222018
4. Martins OM, Fonseca VF, Borges I, Martins V. C-Reactive protein predicts acute myocardial infarction during high-risk noncardiac and vascular surgery. Clinics. 2011;66(5):773-6. Available from: https://www.researchgate.net/publication/51521408
5. Guan H, Wang P, Hui R, Edin ML, Zeldin DC, Wang DW. Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem. 2009;55:274-84. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2749215/
6. Kovalenko VM, Kozliuk AS. Kharakterystyka funktsionalnoho stanu peryferychnykh arterii v umovakh khronichnoho systemnoho zapalennia u khvorykh na osteoartroz iz suputnim metabolichnym syndromom. Ukrainskyi kardiolohichnyi zhurnal. 2015;4:70-7. [in Ukrainian].
7. Khaniukov OO. Riven S-reaktyvnoho bilka plazmy krovi ta stan systemy tsytokiniv u khvorykh z multyfoaklnym aterosklerozom i tsukrovym diabetom. Medytsyna transportu Ukrainy. 2012;1:15-8. Dostupno: http://www.vitapol.com.ua/user_files/pdfs/mtu/4PagesfromMTi1i2012-4. pdf [in Ukrainian].
8. Dzyak GV, Zharіnov OY. Fibrylyatsiya peredserdʹ. K.: Chetverta khvilya; 2011. 192 s. [in Ukrainian].
9. Rebrova OYu. Statisticheskiy analiz meditsinskikh dannykh. Primeneniye paketa prikladnykh programm STATISTICA. Moskva: «MediaSfera»; 2000. 312 s. [in Russian].

«Bulletin of problems biology and medicine» Issue 1 Part 1 (148), 2019 year, 203-206 pages, index UDK 616.125-008.313:616.12-008.331.1:616.12-005.4:616.12-008.315-036.1-074:612.398

10.29254/2077-4214-2019-1-1-148-203-206